Amycretin: A Tracking Guide for a GLP-1 and Amylin Agonist

Amycretin is a single-molecule (unimolecular) GLP-1 and amylin receptor agonist developed by Novo Nordisk, notable for being studied in both subcutaneous and oral forms. By combining GLP-1 and amylin activity in one molecule, it aims to stack two satiety pathways for stronger appetite suppression. Early-phase data published in The Lancet showed substantial weight loss, and in 2025 Novo Nordisk announced plans to advance both the injectable and oral forms into Phase 3 development, beginning in 2026.

Amycretin is investigational and not approved. This is an educational tracking guide, not medical advice or a recommendation.

What it does

• Activates GLP-1 and amylin receptors in a single molecule
• Suppresses appetite through two complementary satiety pathways
• Produced dose-dependent weight loss in early trials, in both oral and injectable forms

Typical protocol shape

In the early trials, amycretin was dose-escalated to manage gastrointestinal tolerability. Because both an oral and a subcutaneous version exist, administration details differ by form, and the oral version would be expected to carry absorption-related timing considerations. All dosing here is trial context, not a recommendation.

What to track daily

• Appetite, portion sizes, and fullness
• Nausea, vomiting, diarrhea, or constipation
• Resting heart rate

What to track weekly

• Bodyweight under consistent conditions
• Waist circumference
• Injection-site tolerance for the subcutaneous form
• Grip strength or a simple lift to watch for muscle loss during rapid loss

Bloodwork worth doing

• Fasting glucose and HbA1c
• Lipid panel over time
• Note thyroid history given the GLP-1 class signal

Realistic expectations

The early numbers are encouraging but come from small, early-phase studies. Late-stage trials will define real efficacy and safety. As with any effective weight-loss agent, part of rapid loss can be lean mass, so protein and resistance training deserve tracking.

Common mistakes

• Overreading early-phase results as settled outcomes
• Ignoring GI tolerability during escalation
• Skipping muscle-preserving habits

Safety notes

Amycretin is investigational, with a risk profile still being established in trials. Expect GLP-1 and amylin class GI effects, and treat any access outside a clinical trial as outside the evidence base. Use only with medical supervision.

Peptid AI is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.